Healthcare Industry News: Glaucoma
News Release - April 27, 2007
Advanced Medical Optics Launches WhiteStar Signature(TM) Phacoemulsification System with Fusion(TM) FluidicsPremium Lens Removal System Combines Proven Performance of Proprietary WHITESTAR(R) Technology with Safety of Revolutionary Fusion(TM) Fluidics to Optimize Patient Outcomes
SAN DIEGO--(HSMN NewsFeed)--Advanced Medical Optics, Inc. (AMO) (NYSE:EYE ) today announced from the American Society of Cataract and Refractive Surgery (ASCRS) Meeting in San Diego the launch of the WhiteStar Signature(TM) phacoemulsification system with Fusion(TM) Fluidics.
The new, advanced technology combines the proven performance of AMO's WhiteStar® technology with the safety of a revolutionary Fusion(TM) dual pump fluidic system. A streamlined user interface and easy-to-use accessories enhance efficiency of the operating room environment.
"The WhiteStar Signature(TM) system combines the efficiency and safety of WhiteStar® phaco technology with improved fluidics that enhance chamber stability," said Dr. David Chang, clinical professor of ophthalmology at the University of California, San Francisco. "The dual pump represents the next generation in phaco fluidics, and the new user interface is a significant improvement for surgeons and staff."
WhiteStar Signature(TM) System With Fusion(TM) Fluidics
One of the most unique features of the WhiteStar Signature(TM) system is its Fusion(TM) Fluidics technology. This system provides the ultimate chamber stability and effectively reduces post-occlusion surge by a significant margin. The dual pump responsiveness has the performance of a venturi pump and the control of a peristaltic flow-based pump to provide a stable environment for the surgeon and patient. The user friendly system includes a one step, one hand cassette, intuitive touch screen and intelligent help feature.
About Advanced Medical Optics (AMO)
AMO develops advanced, life-improving vision technologies for people of all ages. Products in the cataract/implant line include intraocular lenses (IOLs), phacoemulsification systems, viscoelastics, and related products used in ocular surgery. AMO owns or has the rights to such product brands as ReZoom®, Tecnis®, Clariflex®, Sensar®, and Verisyse® IOLs, Sovereign®, Sovereign® Compact and WhiteStar Signature(TM) phacoemulsification systems with WhiteStar® technology, Healon® viscoelastics, and the Baerveldt® Glaucoma shunt. Products in the laser vision correction line include wavefront diagnostic devices, femtosecond lasers and associated patient interface devices, and excimer laser vision correction systems and treatment cards. AMO brands in the laser vision correction business include Star S4 IR®, WaveScan Wavefront®, CustomVue®, IntraLase® FS, IntraLase Method(TM) and IntraLasik®. Products in the contact lens care line include disinfecting solutions, enzymatic cleaners and lens rewetting drops. Among the eye care product brands the company possesses are COMPLETE Moisture PLUS®, COMPLETE® Blink-N-Clean®, Consept®F, Consept® 1 Step, Oxysept® 1 Step, UltraCare®, Ultrazyme®, Total Care(TM) and blink(TM) branded products. AMO is based in Santa Ana, California, and employs approximately 4,200 worldwide. The company has operations in 24 countries and markets products in approximately 60 countries. For more information, visit the company's Website at www.amo-inc.com.
This press release contains forward-looking statements about AMO, including Dr. Chang's statements and those relating to the launch and features of the product. All forward-looking statements in this press release are based on estimates and assumptions and represent AMO's judgment only as of the date of this press release. Actual results may differ from current expectations based on a number of factors including but not limited to market developments, expanded clinical experience, unexpected delays in manufacturing, and unexpected regulatory or quality issues. Therefore, the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any intent or obligation to update these forward-looking statements. Additional information concerning these and other risk factors may be found in previous press releases issued by AMO and AMO's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in AMO's 2006 Form 10-K filed in March 2007. Copies of press releases and additional information about AMO are available at www.amo-inc.com.
Source: Advanced Medical Optics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.